Skip to primary navigation
Skip to main content
Skip to primary navigation
Skip to main content
Toggle Search
Search
Choose which site to search.
Current site
All of UAMS
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller
Cancer Institute
UAMS Health
Jobs
Giving
Toggle Search
Toggle Primary Nav
About
From the Director
Our History
Leadership
Board of Advisors
Health Equity and Workforce Development
About Little Rock
Maps & Directions
Cancer Conversations Calendar
Cancer Institute Magazine
News
College of Medicine
Patient Care
Finding Your Way
Treatment
Prevention & Screenings
Patient Support
Clinical Trials
Research
Research Programs
Membership
Internal Funding
Shared Resources
Training and Education
Get Involved
Donate
Fundraising Events
Volunteer Services & Auxiliary
The Envoys
Contact
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute
All Clinical Trials
Lung Cancer
Trials: Lung Cancer
You are here:
Find a Clinical Trial
All Clinical Trials
Lung Cancer
NCT03851445 – LUNGMAP – A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
June 20, 2024
NCT04214262 – S1914 – A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
June 20, 2024
NCT04625647 – S1900E, A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
June 20, 2024
NCT05061550 – A Phase II Open-label, Multicenter, Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer (NeoCOAST-2)
June 20, 2024
NCT05096663 – S1900G, “A Randomized Phase II Study of INC280 (capmatinib) plusOsimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplifiedStage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)”
June 20, 2024
NCT05633602 – S2302, PRAGMATICA – LUNG: “A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
June 20, 2024
NCT05740566 – A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared with Standard of Care in Subjects with Relapsed Small Cell Lung Cancer after Platinum-based First-line Chemotherapy (DeLLphi-304)
June 20, 2024
NCT05815160 – A Phase 1, Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination with Carboplatin and Etoposide in Adult Participants with Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
June 20, 2024
NCT06031688 – S1900K A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
June 20, 2024